Search

Search Constraints

You searched for: Author/Creator Arnulf, Bertrand

Search Results

1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Issue 2 (February 2020)

2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Issue 10192 (6th July 2019)

3. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma. (3rd February 2020)

4. CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment. Issue 3 (21st June 2022)

5. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. (15th December 2019)

6. Diagnostic score of cardiac involvement in AL amyloidosis. (10th July 2019)

8. FC 114: Monoclonal Gammopathy in Kidney Transplanted Patients: Novel Insights into Long-Term Outcomes. (3rd May 2022)

9. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Issue 3 (20th January 2021)

10. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Issue 6 (11th May 2020)